Key Points
- Director Mir Imran bought 36,000 Rani Therapeutics shares at an average price of $0.69, investing $24,840 and increasing his direct stake by 1.73% to 2.12 million shares.
- RANI opened at $0.82, with a market capitalization of approximately $101.5 million; the stock has traded between $0.44 and $3.87 over the past year.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $8.75, while the company’s latest quarterly loss was narrower and revenue higher than expected.
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) CEO Talat Imran sold 8,014 shares of Rani Therapeutics stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $1.41, for a total transaction of $11,299.74. Following the sale, the chief executive officer directly owned 486,737 shares in the company, valued at $686,299.17. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Talat Imran also recently made the following trade(s):
- On Friday, July 17th, Talat Imran acquired 35,000 shares of Rani Therapeutics stock. The shares were purchased at an average cost of $0.72 per share, for a total transaction of $25,200.00.
Rani Therapeutics Price Performance
Shares of NASDAQ RANI opened at $0.82 on Wednesday. The company has a 50 day simple moving average of $0.81 and a 200 day simple moving average of $1.03. Rani Therapeutics Holdings, Inc. has a 1 year low of $0.44 and a 1 year high of $3.87. The firm has a market cap of $101.49 million, a PE ratio of -2.00 and a beta of 0.78.
Rani Therapeutics (NASDAQ:RANI - Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The company had revenue of $1.71 million for the quarter, compared to analyst estimates of $1.12 million. As a group, research analysts anticipate that Rani Therapeutics Holdings, Inc. will post -0.17 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Jefferies Financial Group Inc. purchased a new position in Rani Therapeutics during the fourth quarter worth about $40,000. Virtu Financial LLC purchased a new stake in Rani Therapeutics in the 4th quarter valued at about $69,000. OMERS ADMINISTRATION Corp purchased a new stake in Rani Therapeutics in the 4th quarter valued at about $93,000. Farallon Capital Management LLC bought a new position in shares of Rani Therapeutics during the 4th quarter worth approximately $105,000. Finally, Kestra Private Wealth Services LLC lifted its position in shares of Rani Therapeutics by 44.8% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company's stock worth $113,000 after buying an additional 70,002 shares in the last quarter. Hedge funds and other institutional investors own 30.19% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on RANI. Lake Street Capital assumed coverage on shares of Rani Therapeutics in a research report on Tuesday, April 14th. They set a "buy" rating and a $9.00 target price on the stock. Weiss Ratings cut shares of Rani Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 17th. Wall Street Zen raised shares of Rani Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, May 17th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $5.00 price objective on shares of Rani Therapeutics in a report on Wednesday, May 20th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $8.75.
Get Our Latest Analysis on RANI
Rani Therapeutics Company Profile
(
Get Free Report)
Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company's proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.
Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
